DD01 – GLP-1/Glucagon Dual Agonist for the Treatment of MASH
Time: 2:30 pm - 3:00 pm
day: Day One
Details:
- Developing a once weekly dual agonist of GLP-1 and glucagon receptors
- Exploring the benefits of half-life extension in obese/overweight patients with type 2 diabetes and MAFLD
- Assessing the benefits of DD01 in its ability to augment incretin therapy, acting through the glucagon receptor and enhancing liver lipolysis to treat the liver first
